RecruitingNot applicableNCT06615206
A First-in-Human Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of a Novel CRISPR RNA-editing Therapy in Patients with Mecp2 Duplication Syndrome, a Rare Orphan Disease (HERO)
Studying Proximal Xq28 duplication syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- HuidaGene Therapeutics Co., Ltd.
- Principal Investigator
- Study Director
- Intervention
- HG204(genetic)
- Enrollment
- 6 enrolled
- Eligibility
- 2-18 years · MALE
- Timeline
- 2024 – 2026
Study locations (1)
- Peking University First Hospital, Beijing, Beijing Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06615206 on ClinicalTrials.gov